biomedical breakthrough Archives - Amazing Health Advances

New Biodegradable Adhesive Offers Safer Alternative for Knee Meniscus Repair

The AHA! Team — Wed, 21 May 2025 05:40:28 +0000

Taipei Medical University via News-Medical – Prof. Jia-Lin Wu’s research team from Taipei Medical University, Taiwan, has developed an advanced biodegradable tissue adhesive to repair torn knee menisci. This innovative adhesive offers a safer and more effective alternative to traditional sutures, paving the way for improved recovery and reduced surgical complications for millions of patients. Natural polymers improve meniscus repair with biodegradable adhesive Meniscus tears, a common knee injury for athletes and older adults, are often treated with sutures that can damage healthy tissue and lead to poor healing. The newly developed adhesive, called ChitHCl-DDA, is made from natural polymers (chitosan and dextran) and demonstrates high adhesive strength, biocompatibility, and biodegradability, making it ideal for meniscus repair. This advancement can improve outcomes for athletes, older adults, and others who face this common injury, as well as reduce the burden on healthcare systems. ChitHCl-DDA: Strong, biocompatible, and designed for seamless healing The ChitHCl-DDA adhesive exhibits strong adhesion and biocompatibility, forming a durable bond with meniscus tissue even in wet environments while supporting natural healing without harmful side effects. It promotes tissue regeneration by encouraging cell migration and collagen formation, which is essential for effective recovery. Designed for controlled degradation, the adhesive provides mechanical support during healing and gradually disappears as the tissue regenerates. Laboratory and animal studies demonstrated its effectiveness, showing significant improvements in tissue healing, reduced extrusion, and enhanced regeneration compared to untreated controls. “Our innovative ChitHCl-DDA adhesive not only bonds strongly in challenging wet conditions but also actively promotes natural tissue regeneration—paving the way for a less invasive and more efficient approach to meniscus repair,” said Prof. Wu. Rigorous testing behind ChitHCl-DDA’s success The research team synthesized the adhesive using chitosan hydrochloride and oxidized dextran, forming a gel-like material that bonds through a chemical reaction. This adhesive sets quickly (2-5 minutes), ensuring it remains in place during surgery. It was tested rigorously for strength, swelling, and biocompatibility, using advanced techniques like Fourier Transform Infrared Spectroscopy and rheological analysis. The adhesive was also tested successfully on porcine and rabbit models to confirm its real-world applicability. This new adhesive could reduce reliance on sutures and associated complications, providing a less invasive and more effective solution for meniscus repair. Beyond orthopedics, the technology may inspire further applications in tissue repair and regenerative medicine, impacting various medical fields. Source: Taipei Medical University Journal reference: Wong, P.-C., et al. (2024). Injectable ChitHCl-DDA tissue adhesive with high adhesive strength and biocompatibility for torn meniscus repair and regeneration. International Journal of Biological Macromolecules. doi.org/10.1016/j.ijbiomac.2024.132409. To read the original article click here.

The post New Biodegradable Adhesive Offers Safer Alternative for Knee Meniscus Repair appeared first on Amazing Health Advances.

Dad’s Quest to Aid Son Leads to Stroke-Recovery Technology

The AHA! Team — Wed, 09 Oct 2024 08:31:39 +0000

John Jeffay via Israel21c – BRAIN.Q helmet’s tailored, low-intensity, low-frequency electromagnetic stimulation aims to enhance and accelerate the brain’s recovery after stroke. Yaron Segal has, like many thousands of enterprising Israelis, identified a problem. And like so many in a country driven by technological innovation, he’s established a startup to find a solution. But he’s not so interested in the payday “exit” that attracts most entrepreneurs in the Startup Nation. His ultimate goal is to find a treatment for his son Lear, born 23 years ago born with familial dysautonomia, a rare and progressive genetic neurological disorder. Segal is not an obvious candidate for the job. He trained as a physicist, specializing in climate, satellites, and three-dimensional models of the atmosphere. But when Lear was diagnosed at the age of three months, Segal decided that he would devote his energy, passion and intellect to finding an effective treatment. Remarkable discoveries He isn’t there yet, but in the long – and often frustrating – process of trying, he has made some remarkable discoveries about the brain’s ability to repair itself, and has developed a treatment that has the potential to help stroke patients live more independent lives. Segal is confident that the same technology will, at some point in the future, also benefit people living with depression, PTSD, ADHD, spinal cord injuries, traumatic brain injuries and other brain-related conditions … and familial dysautonomia. His noninvasive, cloud-based “brainwave helmet” activates a low-intensity electromagnetic field around the patient’s head. In clinical trials with stroke patients, it was demonstrated the treatment significantly improved outcomes in the treated group compared to the control group. It is believed that the investigational technology device encourages the growth of new links between brain cells – links that can get broken by a trauma, or in the case of familial dysautonomia, never existed in the first place. BRAIN.Q, the startup Segal cofounded in 2016, now has 25 staff in Israel and the USA and has attracted $50 million in funding. The crazy guy Segal was, as he puts it, “the crazy guy” who became convinced that the adult brain was capable, with encouragement, of repairing itself. Not completely, but significantly. His theory flew in the face of received medical wisdom. “Neuroplasticity” is the brain’s ability to change and adapt throughout a person’s life and reorganize its structure, functions and connections in response to new experiences, learning or environmental changes. But that couldn’t happen fully in damaged parts of the brain where there is no neural activity – until Segal’s breakthrough. He started experimenting in 2010, funded by friends and family, and within two years he’d shown that mice and rats could, with an early form of his treatment, learn to walk and function again after suffering a brain injury or a broken spinal cord. A potential investor showed the raw data from Segal’s experiment to an expert, who simply refused to accept it was possible. The dismissive response, Segal recalls, was: “I don’t believe it happened. You cannot revive links between cells.” Segal was disappointed but not dismayed. The next step was to test his breakthrough on humans. Faster recovery In a clinical trial conducted in India, stroke patients received the BRAIN.Q therapy using an earlier version of the device for 45 minutes a day, for two months. “The data points to faster recovery of the treated group, indicating that BRAIN.Q’s treatment may not only improve the overall recovery after stroke, but also shorten the recovery period. We hope to test this hypothesis in our ongoing clinical trial,” says Segal. “Some recovered dramatically in the first month, some in the second, depending on how injured the brain was. “People regained everyday function so that they didn’t need help with eating or changing clothes or bathing. “After two months of treatment someone who couldn’t move their legs and was in a wheelchair could walk. Sometimes with a stick, but they could walk.” Tools to fix the problem Stroke is a leading cause of adult disability worldwide. BRAIN.Q’s treatment reduces disability and enhances the potential for recovery. “We are affecting the brain directly, but in a non-invasive manner,” says Segal. “We are affecting the ability of the brain to regenerate connections between cells. “I don’t want to push the brain to do something that it can’t do by itself. I want to harness its natural pattern of waves,” he explains. “You can take a tow truck and drive your broken car all around the city. But I want to take it to the mechanic who will use simple tools and fix the problem.” How did he feel when he saw how the first patients had recovered? “I wanted to cry,” he says. He goes on to relate the story of a woman in Israel who suffered a spinal cord injury in a car crash and has regained control of her legs and bowels, thanks to BRAIN.Q. And there are many more examples. BRAIN.Q, based at the Hebrew University’s Givat Ram campus in Jerusalem, is now conducting trials of the investigational device at patients’ homes after they’ve been discharged from the hospital. “In the beginning I was the CEO because there was nobody else in the company,” says Segal. “Then I became the chief technical officer and now I’m chief of innovation because I think this is where I’m doing the best work I can do.” Can he help his son? Although his son Lear’s diagnosis set him on this journey, Segal eventually honed in on treating strokes because, in neurological terms, they are less complex than familial dysautonomia (also known as Riley-Day syndrome). Familial dysautonomia, particularly prevalent among individuals of Ashkenazi Jewish descent, affects the autonomic nervous system that controls involuntary bodily functions such as breathing, swallowing, digestion, tear production and muscle stability. Lear doesn’t have natural tears, can’t drink liquids, has to eat condensed food, and needs to be held while attempting to walk. In addition, he had spinal fusion surgery at the age of 10. “The most serious situation is when he is in crisis, meaning that whenever he has stress, his autonomic nervous system tries to balance his blood pressure, temperature and chemical balance, and fails. His body goes into ‘panic’ conditions, very similar to those when a normal person is bitten by a snake — he starts to vomit, his blood pressure skyrockets, his temperature increases,” Segal says. “The only way to help him is using medication that brings his autonomic nervous system to a halt, causing it to reset and resume normal operation.” Segal is hopeful that, in time, BRAIN.Q will find a way to re-grow neural links in people with this condition. Meanwhile, he is gratified that the technology can aid stroke patients. For more information, click here. To read the original article click here.

The post Dad’s Quest to Aid Son Leads to Stroke-Recovery Technology appeared first on Amazing Health Advances.

New Nanobiomaterial from the Silk of a Mite with ‘Promising Biomedical Properties’

AHA Publisher — Fri, 01 Jan 2021 08:00:15 +0000

Universidad De La Rioja via EurekAlert – An international team of researchers has developed a new nanomaterial from the silk produced by the Tetranychus lintearius mite. This nanomaterial has the ability to penetrate human cells without damaging them and, therefore, has “promising biomedical properties”. The Nature Scientific Reports journal has published an article by an international scientific team led by Miodrag Grbi?, a researcher from the universities of La Rioja (Spain), Western Ontario (Canada) and Belgrade (Serbia), in its latest issue entitled ‘The silk of gorse spider mite Tetranychus lintearius represents a novel natural source of nanoparticles and biomaterials’ (https://www.nature.com/articles/s41598-020-74766-7). In it, researchers from the Murcian Institute for Agricultural and Food Research and Development (IMIDA), the Barcelona Institute of Photonic Sciences, the University of Western Ontario (Canada), the University of Belgrade (Serbia) and the University of La Rioja describe the discovery and characterisation of this mite silk. They also demonstrate its great potential as a source of nanoparticles and biomaterials for medical and technological uses. The interest of this new material, which is more resistant than steel, ultra flexible, nano-sized, biodegradable, biocompatible and has an excellent ability to penetrate human cells without damaging them, lies in its natural character and its size (a thousand times smaller than human hair), which facilitates cell penetration. These characteristics are ideal for use in pharmacology and biomedicine since it is biocompatible with organic tissues (stimulates cell proliferation without producing toxicity) and, in principle, biodegradable due to its protein structure (it does not produce residues). Researcher Miodrag Grbi?, who heads the international group that has researched this mite silk, highlights “its enormous potential for biomedical applications, as thanks to its size it is able to easily penetrate both healthy and cancerous human cells”, which makes it ideal for transporting drugs in cancer therapies, as well as for the development of biosensors to detect pathogens and viruses. THE ‘RIOJANO BUG’ Tetranychus lintearius is an endemic mite from the European Atlantic coast that feeds exclusively on gorse (Ulex europaeus). It is around 0.3 mm in size, making it smaller than the comma on a keyboard, while the strength of its silk is twice as high as standard spider silk. It is a very rare species that has only been found so far in the municipality of Valgañón (La Rioja, Spain), in Sierra de la Demanda. It was located thanks to the collaboration of Rosario García, a botanist and former dean of the Faculty of Science and Technology at the University of La Rioja, which is why researchers call it “the Rioja bug” (“El Bicho Riojano”). The resistance of the silk produced by Tetranychus lintearius is twice that of spider silk, a standard material used for this type of research, and stronger than steel. It also has advantages over the fibres secreted by the silkworm due to its higher Young’s modulus, its electrical charge and its smaller size. These characteristics, along with its lightness, make it a promising natural nanomaterial for technological uses. This finding is the result of work carried out by the international group of researchers led by Miodrag Grbi?, who sequenced the genome of the red spider Tetranychus urticae in 2011, publishing the results in Nature: https://www.nature.com/articles/nature10640. Unlike the red spider (Tetranychus urticae), the gorse mite (Tetranychus lintearius) produces a large amount of silk. It has been reared in the laboratories of the Department of Agriculture and Food of the University of La Rioja, under the care of Professor Ignacio Pérez Moreno, allowing research to continue. Red spider silk is difficult to handle and has a lower production rate. To read the original article click here.

The post New Nanobiomaterial from the Silk of a Mite with ‘Promising Biomedical Properties’ appeared first on Amazing Health Advances.